National Collaborating Centre for Women's and Children's Health

6th Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people Guideline Development Group meeting

Wednesday 6th November 2013 10am – 4.00pm at RCOG

Present:

leuan Davies (ID) GDG Chair

Mike Thomson (MTn) Consultant gastroenterologist

Dianne Jones (DJ) Health visitor

Mark Tighe (MTe) Paediatric Consultant

John Martin (JM) GP Tom McAnea (TM) GP

Rebecca Harmston (RH)

Bruce Jaffray (BJ)

Karen Bythe (KB)

Sarah Currell (SC)

Lay member

Surgeon

Nurse

Dietician

Rowena Mcartney (RM) Paediatric pharmacist

Eleanor Jeans (EJ) Lay member

NCC staff:

Jiri Chard (JC) Senior research fellow and team leader

Stephen Murphy (SM)

Nitara Prasannan (NP)

David Bevan (DB)

Hannah-Rose Douglas (HRD)

Clinical co-director

Research associate

Project manager

Health economist

In attendance:

Sarah Dundson (SD) Guidelines Commissioning Manager, NICE

Apologies

Charlie Fairhurst (CF)

Consultant in Paediatric Neurodisability

Russell Peek (RP) Consultant Paediatrician with an interest in neonatal

Medicine

1. Welcome, housekeeping, introductions and apologies

ID welcomed the group to the sixth meeting of this guideline development group (GDG) and introduced himself as the Chair.

2. Declarations of interest

MT declared:

Personal non -pecuniary interest:

Was an author of a study which was discussed in the evidence summary at during this GDG meeting – "Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined

intraluminal impedance/pH". Del Buono R, Wenzl TG, Ball G, Keady S, Thomson M. Arch Dis Child. 2005 May;90(5):460-3."

IHD stated this would be recorded, but it was agreed that it did not require MT to be excluded from the discussion.

3. Introduction to Health Economics

HRD gave a presentation on the role of health economics in the guideline development process. After the presentation, the group had an opportunity to ask questions.

4. Presentation of alginates and antacids for the treatment of GOR

NP and MTe presented the evidence review on alginates and antacids for the treatment of GOR.

Break

5. Evidence review on alginates and antacids for the treatment of GOR

The GDG discussed the evidence review on alginates and antacids for the treatment of GOR and drafted their recommendations

Lunch

6. Presentation of medical management for the treatment of GOR

JC and RM presented the evidence review on medical management for the treatment of GOR.

7. Evidence review on medical management for the treatment of GOR

The GDG discussed the evidence review on medical management for the treatment of GOR and drafted their recommendations

Break

8. Any other business

There was no other business. ID thanked the participants for attending and closed the meeting.

Signed:	Date:
leuan Davies, GDG Chair	
Signed:	Date:
Stephen Murphy, Clinical Co-Director (Children's Health)	